AURORA 1 reports efficacy of voclosporin in lupus nephritis

被引：2
|
作者：
Moroni, Gabriella [1 ,2 ]
Ponticelli, Claudio [3 ]
机构：
[1] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[2] IRCCS Humanitas Res Hosp, Milan, Italy
[3] IRCCS Osped Maggiore Policlin, Nephrol, Milan, Italy
来源：
NATURE REVIEWS NEPHROLOGY | 2021年 / 17卷 / 10期
关键词：
CYCLOSPORINE;
D O I：
10.1038/s41581-021-00460-0
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The AURORA 1 study reports that low-dose voclosporin added to standard immunosuppressive treatment improved rate of remission in patients with lupus nephritis. Further studies are needed to investigate the long-term efficacy and tolerability of voclosporin and to compare the effects of this treatment with those of low doses of tacrolimus or ciclosporin.
引用
收藏
页码：637 / 638
页数：2
相关论文
共 50 条
  • [31] AURORA PHASE 3 TRIAL DEMONSTRATES VOCLOSPORIN STATISTICAL SUPERIORITY OVER STANDARD OF CARE IN LUPUS NEPHRITIS (LN)
    Gibson, Keisha
    Parikh, Samir
    Saxena, Amit
    Solomons, Neil
    Randhawa, Simrat
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 75 (05) : 819 - 819
  • [32] Long-term Safety and Efficacy of Voclosporin in Hispanic and Latino Patients with Lupus Nephritis
    Ginzler, Ellen M.
    Saxena, Amit
    Bal, Victoria
    Birardi, Vanessa
    Leher, Henry
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 710 - 712
  • [33] AURORA PHASE 3 TRIAL DEMONSTRATES VOCLOSPORIN STATISTICAL SUPERIORITY OVER STANDARD OF CARE IN LUPUS NEPHRITIS (LN)
    Caster, Dawn J.
    Solomons, Neil
    Randhawa, Simrat
    Huizinga, Robert B.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 119 - 119
  • [34] Voclosporin: A Novel Calcineurin Inhibitor for the Treatment of Lupus Nephritis
    McArn, Ann C.
    Nixon, Alexander R.
    Jarrell, Katherine L.
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (11) : 1267 - 1274
  • [35] Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis
    Mejia-Vilet, Juan M.
    Romero-Diaz, Juanita
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 (09) : 937 - 945
  • [36] Journal Club: Efficacy and Safety of Voclosporin Versus Placebo for Lupus Nephritis (AURORA 1): A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Phase 3 Trial
    Rubio, Jose
    Kyttaris, Vasileios
    ACR OPEN RHEUMATOLOGY, 2021, 3 (12) : 827 - 831
  • [37] TRIAL IN PROGRESS: VOCLOSPORIN IN ADOLESCENTS WITH LUPUS NEPHRITIS (VOCAL)
    Waddingham, Nicola
    Rosales, Amber
    Cheung, Gigi
    Potter, Blake
    Palmen, Mary
    Collins, Christopher
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2023, 81 (04) : S90 - S90
  • [38] AURION STUDY: PRELIMINARY RESULTS OF VOCLOSPORIN IN LUPUS NEPHRITIS
    Yahya, R.
    Gafor, A. H. B. A.
    Huizinga, R.
    Chan, T. M.
    Solomons, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1049 - 1050
  • [39] Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis
    van Gelder, Teun
    Lerma, Edgar
    Engelke, Kory
    Huizinga, Robert B.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (05) : 515 - 529
  • [40] THE EFFICACY OF VOCLOSPORIN IN LUPUS NEPHRITIS IS INDEPENDENT OF CHANGES IN ANTI-DSDNA AND COMPLEMENT AT WEEK 52
    Diamond, Betty
    Truman, Matt
    Mina-Osorio, Paola
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (04) : S2 - S2
12345